top of page
Search Results

334 items found for "Addex Therapeutics"

Posts (198)

View All

Other Pages (136)

  • 22-04 Dr GPCR Newsletter

    Effector membrane translocation biosensors reveal G protein and βarrestin coupling profiles of 100 therapeutically Therapeutics speaks on the Empowered Patient Podcast about Applying Allosteric Modulator Pharmacology Therapeutics Ltd announced that patient enrollment has been completed in its Phase 2a clinical study Therapeutics moves a selective and potent M4 muscarinic receptor positive allosteric modulator (PAM) R-Bridge Healthcare Fund, an affiliate of CBC Group Ono Enters into Collaboration Agreement with Domain Therapeutics

  • 22-01 Dr GPCR Newsletter

    Juan Jose Fung , principal scientist at GPCR Therapeutics followed by Dr. Nicola Smith and Dr. Pina Cardarelli , CSO of GPCR Therapeutics. Are you going to be our next podcast guest? G-protein-coupled receptors as therapeutic targets for glioblastoma. CB1 Blocker and Provides Strategy Update Learn more about Neurocrine Biosciences with their new video Addex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesia Verily links up with Sosei

  • 22-03 Dr GPCR Newsletter

    contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic GPCR Systems Pharmacology: A Different Perspective on the Development of Biased Therapeutics. Law, as their new Chief Business Officer Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment Of Neuropathic Pain Addex Therapeutics, a clinical-stage pharmaceutical Keystone Symposia in-person meeting- GPCRs: An Odyssey from Structure, Signaling, and Regulation to Therapeutics

View All